Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M

NEUROCRINE BIOSCIENCES INC

2025-Q3 EPS reported $3.19 revenue$2,055,000,000

GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.
INGREZZA net sales $686.6M (+12% YoY) driven by record quarterly new and total prescriptions.
CRENESSITY launch generated $98.1M net sales with 540 new patient enrollment start forms.
FY2025 INGREZZA guidance reaffirmed at $2.50-2.55B; GAAP R&D $1.00-1.02B, SG&A $1.14-1.16B.
Initiated second Phase 3 trial for direclidine (schizophrenia); osavampator Phase 3 in MDD enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.